Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN)

Study Identifier:
D928FC00001
ClinicalTrials.gov Identifier:
NCT06291376
EudraCT Identifier:
N/A
Sponsor:
Alexion Pharmaceuticals, Inc.
Study Contact Information:
1-855-752-2356 or [email protected]
Recruiting

Study Details

Medical Condition
  • Unmapped
Study Drug
  • Drug: Ravulizumab
  • Drug: Placebo
Date
Mar 2024 - Jan 2026
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 18 Years - n/a
Requirements Information
Sex
Female & Male
Age
18 Years - n/a

Study Details

Medical Condition
  • Unmapped
Study Drug
  • Drug: Ravulizumab
  • Drug: Placebo
Date
Mar 2024 - Jan 2026
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 18 Years - n/a years
Requirements Information

Protocol Summary

The primary objective of this study to evaluate efficacy of ravulizumab compared with placebo on proteinuria reduction and change in eGFR in adult participants with IgAN who are at risk of disease progression.

Trial Locations

Location
Status
Location
Research Site
Seoul, Unmapped, 03722
Status
Recruiting
Location
Research Site
Anyang-si, Unmapped, 14068
Status
Recruiting
Location
Research Site
Gwangju, Unmapped, 61469
Status
Recruiting
Location
Research Site
Clayton, Unmapped, 3168
Status
Recruiting
Location
Research Site
Herston, Unmapped, 4029
Status
Recruiting
Location
Research Site
New Taipei City, Unmapped, 23561
Status
Recruiting